Gabitril Potential In Anxiety Is Aided By Favorable Side Effect Profile, Cephalon Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company hopes to add an indication for generalized anxiety disorder by 2006. Cephalon expects anti-epileptic Gabitril will generate $100 mil. in 2004; 70% of use is for neuropsychiatric disorders.
You may also be interested in...
Gabitril Seizure Warning Addresses Off-Label Use Of High Dose
A new bolded warning for Gabitril (tiagabine) highlighting the risk of non-epileptic seizures is needed because some doctors are using the drug off-label at higher than recommended levels, Cephalon Investor Relations Senior Director Chip Merritt said March 16 at the SG Cowen health care conference in Boston
Gabitril Seizure Warning Addresses Off-Label Use Of High Dose
A new bolded warning for Gabitril (tiagabine) highlighting the risk of non-epileptic seizures is needed because some doctors are using the drug off-label at higher than recommended levels, Cephalon Investor Relations Senior Director Chip Merritt said March 16 at the SG Cowen health care conference in Boston
Cephalon Marketing Practices Under Investigation By Philadelphia U.S. Attorney
Cephalon will turn over documents from 1998 to the present regarding "sales and promotional practices" for Provigil, Gabitril and Actiq.